中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
6期
1032-1033,1035
,共3页
甘露聚糖肽%序贯%结肠癌%化疗%CapeOX
甘露聚糖肽%序貫%結腸癌%化療%CapeOX
감로취당태%서관%결장암%화료%CapeOX
Mannatide%Sequential therapy%Colon cancer%Chemotherapy%CapeOX
目的：探讨序贯甘露聚糖肽联合CapeOX化学治疗(化疗)方案治疗Ⅳ期结肠癌的临床疗效。方法：选择2005年2月~2011年10月期间笔者所在医院收治的Ⅳ期结肠癌患者120例,随机分为治疗组、对照组、安慰组,各40例,均施CapeOX化疗方案,同时治疗组住院期间应用甘露聚糖肽注射液,出院后口服甘露聚糖肽胶囊；对照组患者住院期间使用注射用胸腺肽,出院后口服胸腺肽肠溶胶囊,安慰组患者住院期间使用等体积的注射用生理盐水,出院后口服相同剂量淀粉安慰剂。结果：治疗组总有效为67.50%,均高于对照组和安慰组。Ⅲ~Ⅳ度毒副反应发生率为42.50%,与对照组、安慰组比较差异具有统计学意义(P<0.01)。治疗组中位生存期为16.38个月,1年生存率为72.50%,与对照组、安慰组比较差异均具有统计学意义(P<0.05)。结论：甘露聚糖肽序贯治疗晚期结肠癌能有效提高临床疗效,延长生存时间,且降低化疗毒副反应。
目的：探討序貫甘露聚糖肽聯閤CapeOX化學治療(化療)方案治療Ⅳ期結腸癌的臨床療效。方法：選擇2005年2月~2011年10月期間筆者所在醫院收治的Ⅳ期結腸癌患者120例,隨機分為治療組、對照組、安慰組,各40例,均施CapeOX化療方案,同時治療組住院期間應用甘露聚糖肽註射液,齣院後口服甘露聚糖肽膠囊；對照組患者住院期間使用註射用胸腺肽,齣院後口服胸腺肽腸溶膠囊,安慰組患者住院期間使用等體積的註射用生理鹽水,齣院後口服相同劑量澱粉安慰劑。結果：治療組總有效為67.50%,均高于對照組和安慰組。Ⅲ~Ⅳ度毒副反應髮生率為42.50%,與對照組、安慰組比較差異具有統計學意義(P<0.01)。治療組中位生存期為16.38箇月,1年生存率為72.50%,與對照組、安慰組比較差異均具有統計學意義(P<0.05)。結論：甘露聚糖肽序貫治療晚期結腸癌能有效提高臨床療效,延長生存時間,且降低化療毒副反應。
목적：탐토서관감로취당태연합CapeOX화학치료(화료)방안치료Ⅳ기결장암적림상료효。방법：선택2005년2월~2011년10월기간필자소재의원수치적Ⅳ기결장암환자120례,수궤분위치료조、대조조、안위조,각40례,균시CapeOX화료방안,동시치료조주원기간응용감로취당태주사액,출원후구복감로취당태효낭；대조조환자주원기간사용주사용흉선태,출원후구복흉선태장용효낭,안위조환자주원기간사용등체적적주사용생리염수,출원후구복상동제량정분안위제。결과：치료조총유효위67.50%,균고우대조조화안위조。Ⅲ~Ⅳ도독부반응발생솔위42.50%,여대조조、안위조비교차이구유통계학의의(P<0.01)。치료조중위생존기위16.38개월,1년생존솔위72.50%,여대조조、안위조비교차이균구유통계학의의(P<0.05)。결론：감로취당태서관치료만기결장암능유효제고림상료효,연장생존시간,차강저화료독부반응。
To observe the efficacy of Mannatide sequential therapy combined with CapeOX chemotherapy in the treatment of stageⅣcolon cancer.Methods:120 patients with stageⅣcolon cancer in the hospital where the author stayed were selected from February 2005 to October 2011 and were randomly divided into treatment group and control group,each group had 40 cases respectively.Both groups were applied CapeOX chemotherapy,the treatment group were given Mannatide injection during hospitalization, oral administration of Mannatide capsules after discharge;the control group were given thymosin injection during hospitalization,oral administration of thymosin enteric-coated capsules after discharge,the placebo group were given an equal volume of saline injection during hospitalization,oral administration of the same dose starch placebo after discharge.Results:The total effective of treatment group was 67.50%,which was higher than that of the control and placebo group.The incidence ofⅢ~Ⅳdegree of toxicity was 42.50%,with statistically significant difference from the control group and the placebo group (P<0.01).The median survival of treatment group was 16.38 months,1 year survival rate was 72.50%,with statistically significant differences from the control group and the placebo group (P<0.05).Conclusion:The treatment that Mannatide sequential therapy combined with CapeOX chemotherapy in the treatment of stageⅣcolon cancer can improve the clinical efficacy effectively,prolong survival time and reduce the side effects of chemotherapy.
